Pediatric Solid Tumors Clinical Trials

Showing 1-13 of 13 items
1.
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
  • RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether surgery is more effective with or without chemotherapy or which chemotherapy regimen may be more effective in treating young patients with liver cancer. PURPOSE: This phase III trial is studying the side effects of giving doxorubicin hydrochloride together with combination chemotherapy and to compare different chemotherapy regimens to see how well they work in treating young patients with newly diagnosed liver cancer.
  • Diagnoses: Pediatric Solid Tumors
  • Status: Recruiting
2.
3.
4.
5.
6.
7.
8.
9.
  • Study of Late-Occurring Complications in Childhood Cancer Survivors
  • RATIONALE: A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. PURPOSE: This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer.
  • Diagnoses: Pediatric Brain Tumor, Pediatric Solid Tumors
  • Status: Recruiting
10.
11.
12.
  • Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
  • Primary Objective: - To determine the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric patients with recurrent or refractory solid tumors including tumors of the central nervous system. Secondary Objectives: - To characterize the safety and tolerability of cabazitaxel in pediatric patients with recurrent or refractory solid tumors including tumors of the central nervous system. - To characterize the pharmacokinetic (PK) profile of cabazitaxel in pediatric patients with recurrent or refractory solid tumors including tumors of the central nervous system. - To evaluate preliminary anti-tumor activity that may be associated with cabazitaxel in pediatric patients with recurrent or refractory solid tumors including tumors of the central nervous system.
  • Diagnoses: Pediatric Brain Tumor, Pediatric Solid Tumors
  • Status: Recruiting
13.
  • The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects
  • This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. Part 1 (dose escalation study) will identify the recommended Part 2 (tumor-specific expansion study) dose and regimen using a dose-escalation procedure. Approximately 6 to 18 subjects will participate in Part 1 and will receive a starting dose of 3 mg/kg and dose will deescalate or escalate between 1.5 milligram (mg)/kilogram (kg) and 4.5 mg/kg. Up to 6 subjects will be enrolled at one dose level dependent upon the number of subjects at the current dose level, the number of subjects who have experienced a dose limiting toxicity (DLT) at the current dose level, and the number of subjects enrolled but with data pending at the current dose level. Escalation may proceed until either a maximum tolerated dose (MTD) is established, or until the dose in which the median pharmacokinetic parameters consistent with exposure in adults are achieved. Cohorts may be added in order to evaluate additional dose levels. Part 2 consists of four disease-specific cohorts of subjects with tumors known to have BRAF V600 activation (pediatric low-grade gliomas, pediatric high-grade gliomas, Langerhans cell histiocytosis [LCH], and other tumors such as melanoma and papillary thyroid carcinoma [PTC]). Each cohort will enroll at least 10 subjects with a pre-dose and at least 1 post-dose disease assessment. In both the parts of the study, on Day 1, a single first dose will be administered, and repeat dosing will begin on Day 2. PK sampling will be performed on Day 1 and Day 15 for subjects >=25 kg in weight. For subjects <25 kg in weight, blood samples for PK analysis will be collected after repeated administration on Day 15 only. Safety and tolerability will be assessed throughout the study. Treatment with dabrafenib will be continued until disease progression or until no clinical benefit or development of an unacceptable toxicity, or until they withdraw consent or begin a new therapy. At the end of treatment, a final study visit will occur.
  • Diagnoses: Pediatric Solid Tumors
  • Status: Recruiting
Showing 1-13 of 13 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms